Fierce Biotech spoke with Affibody about the plans for its Phase III IL-17A inhibitor izokibep. 

Senior editor James Waldron wrote: "Affibody brought Week 52 data along to EULAR 2026 to remind people of what the drug can do when compared to PsA mainstays like Novartis’ Cosentyx and UCB’s Bimzelx. Affibody’s slides show izokibep holding its own on measurements like a 50% improvement in rheumatology symptoms (ACR50), as well as a 70% improvement and the proportion of patients who saw a 100% improvement in psoriasis area and severity (PASI100)."

Read the full article here.